Launch studies in days, not months. Engage HCPs with real-time insights while data is still being collected. Maximize your market exclusivity window.
Climedo gives pharma and biotech sponsors a direct channel from patient to insight, without the manual bottleneck. Autonomous Data Capture (ADC) means your study data arrives clean, in real time, ready to share with HCPs and KOLs before the last patient visit.
Climedo focuses on late-phase and post-approval studies, Phase III/IV and beyond, where speed to insight decides how much of your market exclusivity you can still put to use.
Launch studies in days, not months, and engage HCPs with real-time insights while data is still being collected. Climedo turns a year-end report into a scientific dialogue that runs alongside your study.
Patent protection in pharma holds for 20 years from filing, in both the EU and the US. In reality, a new treatment rarely gets more than ten or eleven years of exclusivity after launch.
Swift market entry matters for sponsors in pharma, biotech and medtech, as well as CROs with commercialization services. Much of the protection period is spent in product development, regulatory review and reimbursement negotiations. A delay of 24 to 36 months in accessing post-approval data can leave just half a decade to turn Real-World Evidence into medical dialogue.
Valuable data, but too late. Late-phase evidence tends to arrive after the window to act on it has narrowed.
The issue is rarely the quality of the data, but the delay in accessing it, typically 24 to 36 months, with limited time left until patent expiry.
Given the volume of results published each year, standing out takes more than strong data. Static slide decks and PDF reports fall short of the full potential of the evidence.
After launch, patients are no longer drawn by exclusive access to a new therapy. Retention can fall as low as 30% in observational obesity studies and 45% in cognitive impairment studies.
Turn static reports into scientific conversations. Climedo makes late-phase evidence usable while the study is still live.
Digital capture during approval and post-approval studies delivers efficiency gains for every stakeholder, with access to trends and benefits across patient populations while the study is still underway.
Bring together quality-of-life measures, biomarkers and symptom data with real-time access. MSLs can present exactly the data an HCP cares about, down to a specific cohort.
Engaging patients through the Patient Cockpit enrolls them faster and reduces long-term drop-out. Patients who feel involved are also more likely to give a positive testimonial.
3 to 5 days to launch, compared with two to three weeks on legacy EDC.
All servers in Frankfurt, with GDPR at the core. Critical for EU pharma.
Autonomous Data Capture from EHR and HIS sources reduces site burden while feeding Real-World Evidence.
Real-time insights that MSLs can put in front of HCPs while the study runs.
More than 2M patients enrolled, trusted by leading pharma.
Clinical data capture is time-consuming and expensive. Delays in clinical trials, often triggered by slow patient recruitment, high drop-out rates and manual processes, can cost pharmaceutical companies millions every day.
This is where Climedo comes in. Our digital, cloud-based platform connects every source of your study in one place:
For phase I–IV studies, interventional and non-interventional studies and the collection of real-world data (RWD).
ADC
At the center of everything
Everything else builds on it. ADC captures study data from documents, patients and HCPs with near-zero manual entry and feeds every module around it in real time.
See How ADC Works
EDC
Cost-efficient, automated and scalable: Capture data for your clinical studies and surveys electronically with our EDC system – all in one place.
Our EDC SystemeCOA & ePRO
Convenient, secure and fast: Digitally capture all data reported by your patients in the course of a clinical study – on any device and with no app.
Our ePRO SolutionsReal-Time Dashboards
Our interactive dashboards enable you to see real-time visualizations of your clinical trial data and compare patient cohorts across different sites.
Our Real-Time DashboardseConsent &
Televisits
Enrol participants wherever they are: they read and sign the consent on their own device and, when needed, meet the study doctor in a televisit.
Our eConsent & TelevisitsHybrid Trials
Patient-centered and flexible: Combine visits at the site with ePRO and televisits from home, so patients can take part wherever they are.
Our Hybrid Trial Solutions
We'll show you how to start a clinical trial or survey and address your specific needs and desires.
Climedo's intuitive user interface means you'll be onboarded in just a few hours, without the need for programming skills. Get started with your project right away.
Patient centricity and decentralized study designs accelerate your recruitment, with patient adherence above 90% in Climedo studies.
Predefined workflows with complex decision trees including automatic plausibility and validation checks improve the data quality from the time of input.
Achieve significant time savings of up to 49% thanks to reusable form templates and the possibility of decentralized study designs and remote monitoring.
Our cloud-based solution has been tested by state authorities and offers a granular roles and rights assignment for different system users.
Dashboards and smart filter views allow you to view all results in real time and thus anticipate potential problems. Data exports are possible in common formats.
Study sponsor of a pharma study
